Search

Participant taking LOOP DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ASPIRIN FROM 280804 (ANTI-INFLAM AGENTS) within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking T-TYPE CALCIUM-CHANNEL BLOCKER within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking WEIGHT LOSS DRUGS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SECOND GENERATION SULFONYLUREAS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking XANTHINE OXIDASE INHIBITORS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BILE-ACID SEQUESTRANTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SYMPATHOMIMETICS, ORAL AND INHALED within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTICHOLINERGICS + COMBINATION WITH BETA2-AGONIST within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking POTASSIUM SUPPLEMENTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking HMG COA REDUCATACE INHIBITORS (STATINS) within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking VASODILATORS, A MIXED GROUP within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE VERAPAMIL within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking DIGITALIS PREPARATIONS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE DILTIAZEM within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking VASODILATORS WITH DIURETICS, A MIXED GROUP within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking IMMEDIATE-RELEASE VERAPAMIL within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INHIBITORS OF Adenosine Diphosphate (ADP)-INDUCED PLATELET AGGREGATION within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking IMMEDIATE-RELEASE DILTIAZEM within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.